{'fraction_non_alphanumeric': 0.028973509933774833, 'fraction_numerical': 0.004966887417218543, 'mean_word_length': 5.430851063829787, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Cardio-oncology: a tremendous opportunity to improve patient care.

A cardiologist at Vanderbilt University (TN, USA), Daniel J Lenihan is President of the International CardiOncology Society-North America. In 1988, Daniel graduated from the University of Tennessee College of Medicine at Memphis and did his residency at Wright-Patterson Air Force Base in Dayton (OH, USA). Ultimately, he gained a cardiology fellowship from the University of Cincinnati (OH, USA) and went on to become Professor and Director of Cardiovascular Research in the Department of Cardiology at The University of Texas MD Anderson Cancer (TX, USA). He now works as Professor of Medicine and Director of Clinical Research in the Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville (TN, USA) specializing in advanced heart failure medicine and cardio-oncology. For over 20 years, he has been active in clinical research in heart failure, and the main focuses of his work have included hemodynamic assessments, angiogenic growth factor response, novel cardiac biomarkers and optimal methods to prevent or detect heart failure at the earliest stage possible in patients undergoing treatment for cancer.